A novel antibiotic combination of linezolid and polymyxin B octapeptide PBOP against clinical Pseudomonas aeruginosa strains

Abstract Background Antibiotic-resistant Gram-negative bacteria are becoming a major public health threat such as the important opportunistic pathogen Pseudomonas aeruginosa (P. aeruginosa). The present study investigated enhancement of the linezolid spectrum, which is normally used to treat Gram-po...

Full description

Saved in:
Bibliographic Details
Main Authors: Ting Huang (Author), Mao Zeng (Author), Huiyao Fu (Author), Kelei Zhao (Author), Tao Song (Author), Yidong Guo (Author), Jingyu Zhou (Author), Longfei Zhai (Author), Chaolan Liu (Author), Balakrishnan Prithiviraj (Author), Xinrong Wang (Author), Yiwen Chu (Author)
Format: Book
Published: BMC, 2022-08-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_1dbba5ea99664d4a9cecea9f9c2cb4a4
042 |a dc 
100 1 0 |a Ting Huang  |e author 
700 1 0 |a Mao Zeng  |e author 
700 1 0 |a Huiyao Fu  |e author 
700 1 0 |a Kelei Zhao  |e author 
700 1 0 |a Tao Song  |e author 
700 1 0 |a Yidong Guo  |e author 
700 1 0 |a Jingyu Zhou  |e author 
700 1 0 |a Longfei Zhai  |e author 
700 1 0 |a Chaolan Liu  |e author 
700 1 0 |a Balakrishnan Prithiviraj  |e author 
700 1 0 |a Xinrong Wang  |e author 
700 1 0 |a Yiwen Chu  |e author 
245 0 0 |a A novel antibiotic combination of linezolid and polymyxin B octapeptide PBOP against clinical Pseudomonas aeruginosa strains 
260 |b BMC,   |c 2022-08-01T00:00:00Z. 
500 |a 10.1186/s12941-022-00531-5 
500 |a 1476-0711 
520 |a Abstract Background Antibiotic-resistant Gram-negative bacteria are becoming a major public health threat such as the important opportunistic pathogen Pseudomonas aeruginosa (P. aeruginosa). The present study investigated enhancement of the linezolid spectrum, which is normally used to treat Gram-positive bacteria, at inhibiting P. aeruginosa growth. Methods The checkerboard test or time-kill assay were carried out to determine the antibacterial effects of linezolid in cooperation with polymyxin B octapeptide PBOP (LP) against P. aeruginosa based on in vitro model. The protective effect of LP against P. aeruginosa infection was assessed based on a Caenorhabditis elegans (C. elegans) model. Results The synergistic activity and antibacterial effects were significantly increased against P. aeruginosa by LP treatment, while linezolid and PBOP as monotherapies exhibited no remarkably bactericidal activity against the clinical strains. Additionally, LP treatment modified biofilm production, morphology, swimming motility of P. aeruginosa, and protected C. elegans from P. aeruginosa infection. Conclusions This research demonstrates that LP combination has significant synergistic activity against P. aeruginosa, and PBOP is potential to be an activity enhancer. Notably, this strategy improved the antibacterial activity spectrum of linezolid and other anti-Gram-positive agents and represents an effective choice to surmount the antibiotic resistance of bacteria in the long term. 
546 |a EN 
690 |a Polymyxin B octapeptide 
690 |a Linezolid 
690 |a Antibacterial activity 
690 |a Synergistic effect 
690 |a Pseudomonas aeruginosa 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
690 |a Infectious and parasitic diseases 
690 |a RC109-216 
690 |a Microbiology 
690 |a QR1-502 
655 7 |a article  |2 local 
786 0 |n Annals of Clinical Microbiology and Antimicrobials, Vol 21, Iss 1, Pp 1-11 (2022) 
787 0 |n https://doi.org/10.1186/s12941-022-00531-5 
787 0 |n https://doaj.org/toc/1476-0711 
856 4 1 |u https://doaj.org/article/1dbba5ea99664d4a9cecea9f9c2cb4a4  |z Connect to this object online.